 Viralkumar Shah
Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 82 | 2024 | 3258 | 13.800 |
Why?
| | Blood Glucose | 48 | 2024 | 1826 | 6.120 |
Why?
| | Blood Glucose Self-Monitoring | 38 | 2024 | 500 | 6.050 |
Why?
| | Hypoglycemic Agents | 36 | 2023 | 1008 | 5.650 |
Why?
| | Hypoglycemia | 21 | 2023 | 387 | 5.420 |
Why?
| | Insulin | 32 | 2023 | 2083 | 3.910 |
Why?
| | Diabetes Mellitus, Type 2 | 16 | 2023 | 2090 | 3.280 |
Why?
| | Insulin Infusion Systems | 19 | 2023 | 296 | 3.220 |
Why?
| | Osteoporotic Fractures | 6 | 2020 | 57 | 2.790 |
Why?
| | Pancreas, Artificial | 4 | 2023 | 68 | 2.720 |
Why?
| | Bone Density | 10 | 2022 | 432 | 2.440 |
Why?
| | Biosimilar Pharmaceuticals | 4 | 2023 | 25 | 2.340 |
Why?
| | Diabetic Ketoacidosis | 4 | 2022 | 159 | 2.280 |
Why?
| | Fractures, Bone | 7 | 2020 | 373 | 1.890 |
Why?
| | Insulin Aspart | 4 | 2023 | 26 | 1.830 |
Why?
| | Adult | 62 | 2024 | 30814 | 1.680 |
Why?
| | Hyperparathyroidism, Primary | 5 | 2014 | 5 | 1.620 |
Why?
| | Hyperglycemia | 7 | 2022 | 295 | 1.470 |
Why?
| | Humans | 104 | 2024 | 115859 | 1.430 |
Why?
| | Diabetes Mellitus | 4 | 2023 | 905 | 1.380 |
Why?
| | Insulin Glargine | 5 | 2023 | 73 | 1.360 |
Why?
| | Diabetes Complications | 4 | 2020 | 212 | 1.360 |
Why?
| | Femur Neck | 4 | 2022 | 60 | 1.300 |
Why?
| | Young Adult | 31 | 2023 | 10508 | 1.110 |
Why?
| | Cannabis | 3 | 2022 | 381 | 1.030 |
Why?
| | Marijuana Abuse | 2 | 2019 | 208 | 1.020 |
Why?
| | Middle Aged | 37 | 2023 | 27078 | 0.990 |
Why?
| | Glucose | 6 | 2023 | 903 | 0.990 |
Why?
| | Male | 47 | 2024 | 56103 | 0.910 |
Why?
| | Female | 49 | 2024 | 60070 | 0.900 |
Why?
| | Insulin, Long-Acting | 3 | 2021 | 52 | 0.890 |
Why?
| | Registries | 10 | 2021 | 1772 | 0.890 |
Why?
| | Sweetening Agents | 1 | 2023 | 37 | 0.880 |
Why?
| | Cardiovascular Diseases | 6 | 2022 | 1724 | 0.870 |
Why?
| | Bone and Bones | 2 | 2023 | 283 | 0.860 |
Why?
| | Bone Remodeling | 2 | 2020 | 65 | 0.850 |
Why?
| | Gastroparesis | 2 | 2019 | 8 | 0.840 |
Why?
| | Vitamin D | 3 | 2014 | 341 | 0.830 |
Why?
| | Diabetic Retinopathy | 1 | 2024 | 149 | 0.810 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.800 |
Why?
| | RNAi Therapeutics | 1 | 2021 | 3 | 0.800 |
Why?
| | Risk Factors | 16 | 2022 | 8715 | 0.800 |
Why?
| | Hyperoxaluria, Primary | 1 | 2021 | 14 | 0.790 |
Why?
| | Insulins | 1 | 2022 | 32 | 0.790 |
Why?
| | Adolescent | 26 | 2023 | 17935 | 0.790 |
Why?
| | Automobile Driving | 1 | 2023 | 129 | 0.760 |
Why?
| | Incretins | 1 | 2020 | 15 | 0.730 |
Why?
| | Osteoporosis | 3 | 2020 | 227 | 0.730 |
Why?
| | Self-Management | 2 | 2020 | 126 | 0.720 |
Why?
| | Blindness | 1 | 2020 | 37 | 0.710 |
Why?
| | Bone Resorption | 1 | 2020 | 74 | 0.700 |
Why?
| | Age Factors | 6 | 2020 | 2911 | 0.680 |
Why?
| | Hip Fractures | 1 | 2020 | 75 | 0.670 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2019 | 36 | 0.650 |
Why?
| | Osteogenesis | 1 | 2020 | 184 | 0.630 |
Why?
| | Self Care | 2 | 2018 | 354 | 0.620 |
Why?
| | Parathyroid Hormone | 4 | 2014 | 95 | 0.610 |
Why?
| | Bone Diseases | 1 | 2018 | 58 | 0.600 |
Why?
| | Quality of Life | 3 | 2023 | 2390 | 0.590 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 252 | 0.590 |
Why?
| | Absorptiometry, Photon | 4 | 2022 | 221 | 0.580 |
Why?
| | Drugs, Investigational | 1 | 2017 | 30 | 0.560 |
Why?
| | Calcium | 6 | 2014 | 1103 | 0.560 |
Why?
| | Marijuana Smoking | 1 | 2019 | 224 | 0.540 |
Why?
| | Accidental Falls | 1 | 2018 | 151 | 0.530 |
Why?
| | Fractures, Spontaneous | 1 | 2015 | 14 | 0.530 |
Why?
| | Vitamin D Deficiency | 2 | 2014 | 159 | 0.500 |
Why?
| | Child | 19 | 2023 | 18537 | 0.490 |
Why?
| | Aged | 19 | 2022 | 19292 | 0.480 |
Why?
| | Gallstones | 1 | 2014 | 28 | 0.460 |
Why?
| | Suicide | 1 | 2020 | 501 | 0.460 |
Why?
| | Glucose Intolerance | 1 | 2015 | 137 | 0.450 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 43 | 0.440 |
Why?
| | Cross-Sectional Studies | 7 | 2023 | 4447 | 0.430 |
Why?
| | Pancreatitis | 1 | 2014 | 107 | 0.430 |
Why?
| | Bone Diseases, Metabolic | 3 | 2019 | 53 | 0.400 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 169 | 0.400 |
Why?
| | Autoimmune Diseases | 1 | 2015 | 396 | 0.390 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 4673 | 0.390 |
Why?
| | Diabetic Angiopathies | 3 | 2020 | 244 | 0.390 |
Why?
| | Prospective Studies | 6 | 2023 | 6276 | 0.380 |
Why?
| | Sex Factors | 4 | 2020 | 1741 | 0.370 |
Why?
| | Obesity | 1 | 2023 | 2523 | 0.360 |
Why?
| | Retrospective Studies | 10 | 2024 | 12615 | 0.360 |
Why?
| | Benchmarking | 2 | 2022 | 163 | 0.350 |
Why?
| | Treatment Outcome | 8 | 2020 | 9163 | 0.320 |
Why?
| | Meals | 2 | 2020 | 101 | 0.320 |
Why?
| | Autoantibodies | 2 | 2018 | 1362 | 0.310 |
Why?
| | Prevalence | 5 | 2023 | 2270 | 0.310 |
Why?
| | Phenotype | 1 | 2015 | 2859 | 0.290 |
Why?
| | Reference Values | 2 | 2019 | 745 | 0.290 |
Why?
| | Body Mass Index | 3 | 2020 | 1974 | 0.290 |
Why?
| | Risk Assessment | 3 | 2020 | 2992 | 0.290 |
Why?
| | India | 3 | 2015 | 135 | 0.260 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2416 | 0.250 |
Why?
| | United States | 8 | 2020 | 12319 | 0.250 |
Why?
| | Case-Control Studies | 4 | 2020 | 3054 | 0.240 |
Why?
| | Phosphates | 3 | 2014 | 160 | 0.240 |
Why?
| | Artificial Organs | 1 | 2023 | 2 | 0.220 |
Why?
| | Germany | 2 | 2020 | 88 | 0.220 |
Why?
| | Cross-Over Studies | 3 | 2019 | 437 | 0.220 |
Why?
| | Glycemic Index | 1 | 2022 | 21 | 0.210 |
Why?
| | History, 20th Century | 2 | 2014 | 275 | 0.210 |
Why?
| | Insulin Lispro | 1 | 2022 | 35 | 0.210 |
Why?
| | Minority Groups | 2 | 2023 | 232 | 0.210 |
Why?
| | Follow-Up Studies | 2 | 2022 | 4443 | 0.210 |
Why?
| | Biomarkers | 3 | 2023 | 3474 | 0.200 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2022 | 27 | 0.200 |
Why?
| | Sex Characteristics | 2 | 2018 | 643 | 0.200 |
Why?
| | Computer Systems | 2 | 2018 | 46 | 0.190 |
Why?
| | Gastric Emptying | 1 | 2021 | 40 | 0.190 |
Why?
| | Calibration | 2 | 2018 | 127 | 0.190 |
Why?
| | Diabetic Neuropathies | 1 | 2022 | 79 | 0.190 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2020 | 2 | 0.190 |
Why?
| | Energy Intake | 1 | 2023 | 413 | 0.180 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2020 | 14 | 0.180 |
Why?
| | Regression Analysis | 2 | 2020 | 960 | 0.180 |
Why?
| | Austria | 1 | 2020 | 2 | 0.180 |
Why?
| | Skiing | 1 | 2021 | 40 | 0.180 |
Why?
| | Psychometrics | 2 | 2021 | 615 | 0.180 |
Why?
| | Glucagon-Secreting Cells | 1 | 2020 | 20 | 0.180 |
Why?
| | Aged, 80 and over | 3 | 2020 | 6434 | 0.170 |
Why?
| | RNA Interference | 1 | 2021 | 438 | 0.170 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 137 | 0.170 |
Why?
| | Reproducibility of Results | 4 | 2021 | 2807 | 0.170 |
Why?
| | Postprandial Period | 1 | 2020 | 88 | 0.170 |
Why?
| | C-Peptide | 1 | 2020 | 137 | 0.170 |
Why?
| | Insulin Antibodies | 1 | 2020 | 102 | 0.170 |
Why?
| | Bone Development | 1 | 2019 | 48 | 0.170 |
Why?
| | Fatal Outcome | 1 | 2020 | 286 | 0.170 |
Why?
| | Radius | 1 | 2019 | 33 | 0.160 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2021 | 17 | 0.160 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 196 | 0.160 |
Why?
| | Social Class | 1 | 2020 | 210 | 0.160 |
Why?
| | Infusion Pumps, Implantable | 1 | 2018 | 20 | 0.160 |
Why?
| | Healthy Volunteers | 1 | 2019 | 191 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1217 | 0.160 |
Why?
| | Cancellous Bone | 1 | 2018 | 20 | 0.160 |
Why?
| | Methyldopa | 1 | 2018 | 7 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2020 | 207 | 0.150 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 40 | 0.150 |
Why?
| | Postmenopause | 1 | 2020 | 301 | 0.150 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 217 | 0.150 |
Why?
| | Health Behavior | 1 | 2023 | 704 | 0.150 |
Why?
| | Tibia | 1 | 2019 | 172 | 0.150 |
Why?
| | Pelvic Bones | 1 | 2020 | 128 | 0.150 |
Why?
| | Sensitivity and Specificity | 1 | 2022 | 1725 | 0.150 |
Why?
| | HLA-DQ Antigens | 1 | 2018 | 178 | 0.150 |
Why?
| | Pregnancy in Diabetics | 1 | 2018 | 82 | 0.140 |
Why?
| | Glucagon | 1 | 2017 | 93 | 0.140 |
Why?
| | Antigen Presentation | 1 | 2018 | 189 | 0.140 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 962 | 0.140 |
Why?
| | Uric Acid | 1 | 2018 | 150 | 0.140 |
Why?
| | Biosensing Techniques | 1 | 2018 | 102 | 0.140 |
Why?
| | Computer-Aided Design | 1 | 2017 | 40 | 0.140 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 119 | 0.140 |
Why?
| | Hormones | 1 | 2017 | 132 | 0.140 |
Why?
| | Antibody Formation | 1 | 2018 | 274 | 0.140 |
Why?
| | Health Personnel | 1 | 2022 | 579 | 0.140 |
Why?
| | Circadian Rhythm | 1 | 2019 | 371 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2018 | 263 | 0.140 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 318 | 0.130 |
Why?
| | Alkaline Phosphatase | 2 | 2014 | 144 | 0.130 |
Why?
| | Drug Design | 1 | 2017 | 156 | 0.130 |
Why?
| | Drug Overdose | 1 | 2020 | 295 | 0.130 |
Why?
| | Energy Metabolism | 1 | 2020 | 713 | 0.130 |
Why?
| | Diabetic Nephropathies | 1 | 2018 | 234 | 0.120 |
Why?
| | Time Factors | 2 | 2022 | 6182 | 0.120 |
Why?
| | Dietary Supplements | 1 | 2018 | 460 | 0.120 |
Why?
| | Parathyroidectomy | 1 | 2014 | 7 | 0.120 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.120 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 7 | 0.120 |
Why?
| | Allylamine | 1 | 2013 | 7 | 0.110 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 10 | 0.110 |
Why?
| | Bromocriptine | 1 | 2013 | 27 | 0.110 |
Why?
| | Insulin Detemir | 1 | 2013 | 8 | 0.110 |
Why?
| | History, 21st Century | 1 | 2014 | 164 | 0.110 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2014 | 54 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2590 | 0.110 |
Why?
| | Insulin, Isophane | 1 | 2013 | 17 | 0.110 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 44 | 0.110 |
Why?
| | Bionics | 2 | 2023 | 11 | 0.110 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2013 | 99 | 0.110 |
Why?
| | Islet Amyloid Polypeptide | 1 | 2013 | 47 | 0.110 |
Why?
| | Recurrence | 1 | 2016 | 950 | 0.110 |
Why?
| | Parathyroid Neoplasms | 1 | 2012 | 11 | 0.110 |
Why?
| | Cohort Studies | 2 | 2020 | 4960 | 0.110 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 158 | 0.110 |
Why?
| | Abdominal Pain | 1 | 2014 | 136 | 0.110 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2013 | 101 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2013 | 143 | 0.100 |
Why?
| | Hypoparathyroidism | 1 | 2012 | 4 | 0.100 |
Why?
| | Pregnancy | 2 | 2021 | 5555 | 0.100 |
Why?
| | Dogs | 1 | 2013 | 344 | 0.100 |
Why?
| | Leptin | 1 | 2013 | 211 | 0.100 |
Why?
| | Hemoglobins | 1 | 2014 | 313 | 0.100 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2012 | 65 | 0.100 |
Why?
| | Algorithms | 2 | 2018 | 1494 | 0.100 |
Why?
| | Cholelithiasis | 1 | 2011 | 31 | 0.090 |
Why?
| | Swine | 1 | 2013 | 705 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 589 | 0.090 |
Why?
| | Adenoma | 1 | 2012 | 187 | 0.090 |
Why?
| | Consensus | 2 | 2023 | 531 | 0.090 |
Why?
| | Animals | 4 | 2018 | 32158 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1758 | 0.090 |
Why?
| | Heart Failure | 1 | 2023 | 1963 | 0.090 |
Why?
| | Metformin | 1 | 2013 | 278 | 0.090 |
Why?
| | Exercise | 1 | 2020 | 1611 | 0.090 |
Why?
| | Colorado | 1 | 2019 | 4122 | 0.080 |
Why?
| | Pilot Projects | 3 | 2021 | 1379 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1193 | 0.070 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1088 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2023 | 99 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2022 | 33 | 0.050 |
Why?
| | Needles | 1 | 2022 | 52 | 0.050 |
Why?
| | Off-Label Use | 1 | 2021 | 52 | 0.050 |
Why?
| | Pancreas | 1 | 2023 | 280 | 0.050 |
Why?
| | Sodium | 1 | 2021 | 183 | 0.050 |
Why?
| | Inpatients | 1 | 2023 | 380 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 82 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 944 | 0.040 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 249 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 36 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 250 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2020 | 137 | 0.040 |
Why?
| | Individuality | 1 | 2019 | 146 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2018 | 178 | 0.040 |
Why?
| | Skin | 1 | 2022 | 668 | 0.040 |
Why?
| | United Kingdom | 1 | 2017 | 230 | 0.040 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2018 | 515 | 0.030 |
Why?
| | Patient Compliance | 1 | 2020 | 524 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 431 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 562 | 0.030 |
Why?
| | Child, Preschool | 2 | 2019 | 9164 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1871 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2018 | 605 | 0.030 |
Why?
| | Culture | 1 | 2015 | 126 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2014 | 27 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 563 | 0.030 |
Why?
| | Home Care Services | 1 | 2017 | 226 | 0.030 |
Why?
| | Cholecalciferol | 1 | 2014 | 47 | 0.030 |
Why?
| | Parents | 1 | 2021 | 1208 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 1971 | 0.030 |
Why?
| | Calcifediol | 1 | 2012 | 29 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2022 | 2404 | 0.030 |
Why?
| | Research Design | 1 | 2017 | 949 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 805 | 0.020 |
Why?
| | Tourniquets | 1 | 2011 | 28 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2423 | 0.020 |
Why?
| | Serum Albumin | 1 | 2011 | 135 | 0.020 |
Why?
| | Fasting | 1 | 2011 | 241 | 0.020 |
Why?
| | Infant | 1 | 2019 | 7992 | 0.020 |
Why?
| | Mice | 1 | 2018 | 15085 | 0.010 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|